Last reviewed 2026-04-22 · How we verify

Amorolfine (Antifungal)

Amorolfine inhibits fungal sterol synthesis by blocking lanosterol demethylase, disrupting the integrity of the fungal cell membrane.

Amorolfine inhibits fungal sterol synthesis by blocking lanosterol demethylase, disrupting the integrity of the fungal cell membrane. Used for Onychomycosis (fungal nail infection), Dermatophyte and non-dermatophyte fungal infections of the skin.

At a glance

Mechanism of action

Amorolfine is a morpholine antifungal that selectively inhibits the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungi. This blocks the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic sterol precursors leads to cell membrane dysfunction and fungal cell death.

Approved indications

• Onychomycosis (fungal nail infection)
• Dermatophyte and non-dermatophyte fungal infections of the skin

Common side effects

• Local irritation at application site
• Burning or stinging sensation
• Erythema
• Pruritus

Key clinical trials

• Mycosis Culture Collection From Dermatological Isolated
• Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Amorolfine (Antifungal) CI brief — competitive landscape report
• Amorolfine (Antifungal) updates RSS · CI watch RSS
• Pierre Fabre Dermo Cosmetique portfolio CI